Pharma Focus Asia

Aquavit Life Sciences invests in Biopharmaceutical R&D and Manufacturing facility, South Korea

Introduction:

Aquavit Life Sciences, Inc. announced plans to invest in a new R&D and manufacturing facility in Daegu, South Korea.

Features:

Aquavit will build a facility that is compliant with US FDA regulations for current good manufacturing practices (cGMP). Phase 1 of the project will be a 10,000 sq. ft. space equipped with an ISO 5 class cleanroom under ISO 14644-1 classification.  Aquavit signed a 5 year contract with Kyungbuk National University (KNU) Technopark, which is a science and technology incubation center.

The new location will position the company to enhance its pipeline of personalized medicine products and technology. In addition to developing its own pipeline, Aquavit will partner with domestic pharmaceutical firms in research, global clinical tests, and other ventures.

The city of Daegu has been expanding its commitment to the biotech and pharmaceutical industries and has invested over $ 600 million USD to date in state-of-the-art infrastructure and facilities that support the growing opportunities in these industries.

Specifications:

Company NameAquavit Life Sciences, Inc.
LocationDaegu, South Korea
TypeNew R&D and Manufacturing Facility
Phase 1 of the project10,000 sq. ft. space with an ISO 5 class cleanroom
Contract Signed WithKyungbuk National University
Contract Duration5 years
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference